Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ZYBT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -40.38% | Avg. Invested days 16 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 235.36M USD | Price to earnings Ratio 83.17 | 1Y Target Price - |
Price to earnings Ratio 83.17 | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 3.50 - 14.30 | Updated Date 05/15/2025 |
52 Weeks Range 3.50 - 14.30 | Updated Date 05/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.06 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.69% | Operating Margin (TTM) 15.71% |
Management Effectiveness
Return on Assets (TTM) 3.82% | Return on Equity (TTM) 7.15% |
Valuation
Trailing PE 83.17 | Forward PE - | Enterprise Value 246150989 | Price to Sales(TTM) 1.24 |
Enterprise Value 246150989 | Price to Sales(TTM) 1.24 | ||
Enterprise Value to Revenue 9.48 | Enterprise Value to EBITDA 31.36 | Shares Outstanding 47166400 | Shares Floating 4068874 |
Shares Outstanding 47166400 | Shares Floating 4068874 | ||
Percent Insiders 91.64 | Percent Institutions - |
Upturn AI SWOT
Zhengye Biotechnology Holding Limited Ordinary Shares
Company Overview
History and Background
Zhengye Biotechnology Holding Limited is focused on biotechnology applications. Details regarding its founding year and specific milestones are not readily available in standard financial databases. Further research into the company's filings or official website is recommended for this data.
Core Business Areas
- Biotechnology Research and Development: Development of novel biotechnology solutions across various sectors.
- Biomanufacturing: Production of biotechnological products and therapies.
- Healthcare Solutions: Application of biotechnology to improve health outcomes and treatments.
Leadership and Structure
Information regarding Zhengye Biotechnology Holding Limited's leadership team and organizational structure is not readily available. Direct company resources should be investigated for these details.
Top Products and Market Share
Key Offerings
- Specific Product 1: Details of specific products and their market share are not publicly available. Without further information, it's not possible to describe specific products, market share data, number of users, revenue, or the competitive landscape.
Market Dynamics
Industry Overview
The biotechnology industry is currently experiencing substantial growth, driven by advancements in genetic engineering, personalized medicine, and biomanufacturing. Increasing demand for innovative healthcare solutions fuels this expansion.
Positioning
Zhengye Biotechnology Holding Limited's specific position within the industry requires detailed analysis of its product portfolio, market share, and competitive advantages, which is not currently possible with available data.
Total Addressable Market (TAM)
The global biotechnology market is projected to reach trillions of USD in the coming years. The company's positioning with respect to the TAM is unclear without further details about its market share and target markets.
Upturn SWOT Analysis
Strengths
- Innovative biotechnology solutions
- Potential for growth in emerging markets
Weaknesses
- Limited publicly available information
- Potential for dependency on key personnel
Opportunities
- Partnerships with established pharmaceutical companies
- Expanding into new therapeutic areas
Threats
- Regulatory hurdles
- Competition from larger biotechnology firms
Competitors and Market Share
Key Competitors
Competitive Landscape
A competitive landscape comparison cannot be provided without knowing key competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are not available.
Future Projections: Future growth projections are not available.
Recent Initiatives: Information on recent strategic initiatives is not available.
Summary
Based on limited available information, assessing the company's strength is challenging. Further investigation is needed to understand its financials, product portfolio, and competitive positioning. More data is needed to determine the opportunities and threats the company faces.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Publicly available financial databases and news sources.
Disclaimers:
The information provided is based on limited publicly available data and should not be considered financial advice. Further research is recommended.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zhengye Biotechnology Holding Limited Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2025-01-07 | CEO - | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 278 | Website https://www.jlzybio.com |
Full time employees 278 | Website https://www.jlzybio.com | ||
Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. It offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. The company also exports its products to Vietnam, Pakistan, and Egypt. The company was founded in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.